Newsroom

victoria, british columbia (canada), november 4, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, announces the details of its upcoming techday event on friday, november 15, 2024, from 9:00 a.m. to 12:30 p.m. est in cambridge, massachusetts. this exclusive gathering will highlight ipa’s latest advancements in ai-driven design, biologics innovation, and strategic technological developments. highlights of techday: presentation by dr. dirk van hyfte: van hyfte will present “accelerating drug discovery with lensai: a comprehensive solution.” he will showcase lensai, biostrand’s revolutionary platform, and discuss how it transforms drug discovery by integrating biotechnology, biotherapeutics, and artificial intelligence. key topics include using hyft® universal fingerprints to revolutionize multi-omics and data integration while accelerating drug discovery, development and optimization with ai-driven insights. lensai demo: a live demonstration of the lensai platform, showcasing its capabilities in accelerating and enhancing the discovery and design of therapeutic antibodies through ai-driven insights. presentation by dr. shuji sato: sato will present ipa’s b cell discovery platform and discuss its integration with the company’s advanced ai and ngs workflows for highly efficient hit expansion. this process includes: fast analysis of complete ngs repertoires multimodal feature extraction that combines sequence, structure, and large language model (llm) embeddings to deliver enhanced insights into sample diversity. add-ons that complement outputs from phage display, b-cell, and hybridoma technologies, enabling the retrieval of antibody sequences with characteristics similar to known binders. fireside chat: disruptive dialogue: empowering drug discovery through seamless data integration and ai-powered insights participants: dirk van hyfte, head of innovation and co-founder, biostrand (ipa) jeff fried, director of platform strategy and innovation, intersystems this discussion will explore how vector search intelligence is at the core of the lensai platform, seamlessly integrated with the intersystems iris data platform to deliver precise, scalable solutions that accelerate antibody discovery, enhance accuracy, and increase candidate diversity. ai-driven drug discovery summit usa 2024 additionally, earlier that same week at the ai-driven drug discovery summit usa 2024, ipa will participate in another fireside chat titled beyond conventional biologics: the intersection of machine learning and biological engineering to invent. participants at the ai-driven drug discovery summit usa 2024: adam root, vice president and head of protein sciences, generate biomedicines dirk van hyfte, head of innovation and co-founder, biostrand (ipa) the chat will focus on the integration of artificial intelligence and machine learning with wet lab infrastructure to accelerate biologics development. a recorded webcast of the techday presentations will be available in the investors section of the ipa website under "events and presentations" at ir.ipatherapeutics.com. interested in joining us for this exclusive techday experience? space is limited - secure your spot by contacting jennifer k. zimmons, phd, mba, at quantum media: jen@quantum-corp.com about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “expects” “estimates”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking statements include, but are not limited to, statements regarding the capabilities, impact and results expected from biostrand’s lensai platform. although the company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the united states, canada or internationally. you should also consult our quarterly and annual filings with the canadian and u.s. securities commissions for additional information on risks and uncertainties. these forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source: immunoprecise antibodies ltd.

rabbit b cell select ® drives clinical breakthroughs in cancer treatment victoria, british columbia--(business wire)-- immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today proudly announces the clinical progress achieved with rabbit monoclonal antibodies designed and developed using ipa’s proprietary b cell select ® platform for the clinical-stage company, oncoresponse inc. this achievement underscores ipa’s leadership as a contract research organization creating high-quality therapeutic antibodies, while pioneering work in the field of rabbit monoclonal antibody development. these antibodies are rapidly gaining recognition as a unique tool in therapies due to their distinctive properties, advancing into clinical trials aimed at improving patient outcomes. oncoresponse’s breakthrough in cancer treatment in a live presentation at the recent pegs 2024 conference, oncoresponse shared exciting updates on two novel antibodies, or502 and or641, both of which were discovered and refined using ipa’s innovative b cell select ® platform: or502, a novel, humanized anti-leukocyte immunoglobulin like receptor b2 (lilrb2) antibody, has successfully entered phase i/ii clinical trials, showing excellent safety profile, and is being evaluated for efficacy in treating advanced solid tumors. preclinical models have demonstrated that or502 is a best-in-class anti-lilrb2 antibody that reverses immunosuppression caused by myeloid cells in the tme. or641, a novel, humanized dual antagonist antibody targeting both lilrb1 and lilrb2, has completed cell line development and is undergoing ind-enabling studies. preclinical models have demonstrated its superior ability to reverse immunosuppression caused by myeloid and lymphoid cells compared to other anti-lilrb1/2 antibodies. driving antibody discovery and design for clinical success ipa’s proprietary b cell select ® platform has been instrumental in the rapid design and discovery of antibodies that have advanced to clinical stages for numerous clients. by preserving the natural structure of antibodies, ipa’s technology supports optimal functioning of the therapies in a clinical setting. through comprehensive testing and validation, the process ensures that these antibodies maintain their efficacy and reliability from the lab to the clinic. "at immunoprecise antibodies, our mission is not just to develop antibodies, but to redefine what’s possible in therapeutic interventions," said dr. jennifer bath, president and ceo of ipa. "our innovative platform, built on years of expertise, has consistently delivered antibodies with superior qualities, many of which are now advancing in clinical trials. this reflects our unwavering commitment to innovation and our strategic advantage in the market. we are proud to support our clients in bringing groundbreaking, life-changing treatments to patients around the world, reinforcing the long-term value of our technologies." harnessing rabbit b cell technology for breakthrough antibody discovery the rabbit b cell platform, a rapidly advancing technology in therapeutic antibody development, played a pivotal role in the discovery process. this platform excels at generating high-affinity and highly specific rabbit monoclonal antibodies, a demand met with very limited providers in the market. ipa has successfully utilized their b cell select platform in over 200 antibody programs, achieving remarkable success against a variety of targets, including small molecules, peptides, and proteins. the distinctive properties of rabbit antibodies, combined with ipa’s expertise, have consistently led to the development of promising therapeutic candidates. building on this success, ipa is now offering more complex therapeutic rabbit antibody campaigns as a partnering model, providing companies with greater flexibility in structuring their more complicated programs. outlook the field of rabbit monoclonal antibody (mab) therapeutics is advancing rapidly, driven by innovations in antibody engineering and humanization techniques. these advancements are making rabbit mabs increasingly popular for human therapeutic use. the unique properties of rabbit antibodies, combined with ipa’s full-service technologies, such as in silicohumanization, indicate a strong potential for more rabbit-derived mabs to enter clinical trials and achieve approval in the coming years. the distinctive advantages of rabbit antibodies make them a promising foundation for future therapeutic development. as this technology progresses, ipa remains at the forefront, harnessing these innovations to bring new, effective treatments to the clinic, reinforcing our growing leadership in the industry. dr. kamal d. puri, chief scientific officer of oncoresponse, recognized ipa’s pivotal role in their success, praising the quality and reliability of ipa’s antibody discovery services. “we are thrilled to have worked with ipa to discover our lead therapeutic antibodies. the ipa team’s deep experience and know-how with a battery of customized, high-throughput discovery strategies has played a critical role in the successful discovery of our molecules with unsurpassed speed and efficiency,” said kamal d. puri, chief scientific officer of oncoresponse. about or502 lilrb2 is an immunoinhibitory receptor expressed on tumor-associated macrophages (tams) found in the tumor microenvironment (tme). tams inhibit the activity of checkpoint inhibitor (cpi) therapy and prevent t cells from killing tumors. blocking the inhibitory activity of tams and promoting the activity of tumor-killing t cells reverses inhibition of cpi therapy, potentially leading to more and deeper responses to cpis in patients. this is the mechanism of or502, which modulates lilrb2 by blocking its engagement of hla-g on tumor cells and prevents the suppression of the myeloid cells. elevated expression of lilrb2 correlates with reduced patient survival in various tumor types. this humanized monoclonal antibody, or502, targets lilrb2 and blocks the inhibitory activity of tams and promotes the activity of tumor-killing t cells, reversing inhibition of cpi therapy. about oncoresponse oncoresponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. in a broad strategic alliance with md anderson cancer center, oncoresponse deploys a proprietary b-cell discovery platform to identify and develop novel antibodies targeting immune cells in the tumor microenvironment. the company’s lead clinical candidate, or502 is a best-in-class anti-lilrb2 antibody that rescues innate and adaptive immune responses from lilrb2-mediated immune suppression and has entered clinical study in 2023. or502 clinical studies are being conducted with support from the cancer prevention research institute of texas (cprit) dp230076. additional pipeline candidates that modulate suppressive macrophage activity are under development, including or641, a unique dual anti-lilrb2/1 antagonist antibody that promotes a th1-like immune response. for more information, please visit www.oncoresponse.com and follow us on linkedin and x. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). forward-looking statement this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, and clinical readiness or effectiveness of ipa-discovered therapeutics. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time, those assumptions include: the continued successful of ipa’s technology in discovering and developing antibodies, timely regulatory approval and acceptance of therapies developed using the company’s technologies, the potential for partnerships in antibody discovery and development; and the expectation that these technological advancements will drive increased revenue streams and sustained financial growth for the company. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar ). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com source: immunoprecise antibodies ltd.

ipa’s project revenue increased by 16.7% compared to the prior year, driven by the growth of the company's proprietary b cell select® platform and protein manufacturing services. talem therapeutics has announced a collaboration with libera bio to develop multi-target antibodies including the use of artificial intelligence (ai) technology. the companies will use talem's ai platform to help discover and optimize antibodies for various diseases, including cancer. this collaboration is expected to generate antibodies against disease targets that have historically been undruggable. briacell’s ai-based drug discovery program, after a brief pause due to additional workflows added, is underway and going well. the program is using biostrand’s lensai to analyze and prioritize potential drug targets for cancer treatment. briacell aims to use this technology to accelerate the development of new cancer therapies. biostrand announces the first monetization of its natural language processing (nlp) and immunogenicity modules. these modules are now allowing pharmaceutical companies to extract and analyze data from scientific publications and identify potential immunogenicity issues with drug candidates. biostrand is ramping its efforts to use this technology to help pharmaceutical companies develop safer and more effective drugs. biostrand's saas-based data management platform has been awarded a first-round rfp (request for proposal) by an undisclosed pharmaceutical company. the platform allows researchers to store, manage, and analyze large amounts of genomic, transcriptomic, and proteomic data using ai and hyfts technology. if awarded, this program is expected to help the pharmaceutical company accelerate its drug discovery process and improve its r&d efficiency. minimally, this third-party validation marks the beginning of a new potential revenue stream of great interest and high conceivable revenues for biostrand. victoria, british columbia (canada), march 16, 2023 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal year 2023, which ended january 31, 2023. “we are thrilled to announce that this quarter has been a foundational one for our company. our project revenue has experienced a significant increase, thanks to our recognized best-in-class platform of function-first b cell. in addition, our clients have shown a noticeable trend of moving away from transgenic animals, which may limit genetic diversity of outputs, and towards animals with diverse b cell repertoires and rapid, cost-effective next-generation humanization technologies – capabilities that ipa is again unique positioned to provide”, stated dr. jennifer bath, ceo of ipa. she added, “in addition to our established success, we have ventured into the promising field of modern artificial intelligence, expanding our revenue streams, and providing the first revenue for our subsidiary, biostrand. our newest, unique ai-powered research collaboration may also allow us to tackle previously undruggable targets within the cellular context, and we are excited about the unparalleled value proposition that this could offer our investors. we are equally excited about our ongoing efforts to finalize another ai-driven research collaboration for a complex oncology program with a leading global oncology therapeutics company. these strategic initiatives have been critical in driving growth, innovation, and shareholder value, and we remain confident in our ability to continue to deliver exceptional results. as a company, we are proud of our achievements, and we look forward to the continued success that these initiatives will bring.” third quarter fiscal year 2023 financial summary* (all comparisons are to the period ended january 31, 2022) ipa achieved revenue of $5.2 million during the three months ended january 31, 2023, an increase of 7.4% compared to the three months ended january 31, 2022. project revenue increased 16.7% compared to the prior year. for the nine months ended january 31, 2023, total revenue growth of 10.9% when adjusting for the effect of currency translations. gross profit increased 14.6% to $3.0 million for the three months ended january 31, 2023 as compared to the same period last year. ipa held cash of $11.4 million as of january 31, 2023. *expressed in canadian dollars, unless otherwise indicated. financial results revenue & gross profit ipa achieved revenue of $5.2 million during the three months ended january 31, 2023, a 7.4% increase from the three months ended january 31, 2022. project revenue increased 16.7% compared to the prior year, driven by growth in the company’s b cell select® platform and protein manufacturing services. gross profit increased 14.6% to $3.0 million from the same period last year. liquidity and capital resources as of january 31, 2023, ipa held $11.4 million of cash, as compared to $30.0 million as of april 30, 2022, and had working capital of $12.2 million. ipa does not hold cash at silicon valley bank and has not seen any impact on our business from the collapse and subsequent take-over of the bank. polytope® taxt-03 antibody combination therapy talem, ipa's subsidiary, has experienced unanticipated delays in the production of its anti-covid therapeutic drug product, polytope, and has adjusted its milestones accordingly, having yet to receive the drug product from its cdmo partner, chempartner. talem is working closely with chempartner to negotiate a mutually beneficial outcome. due to these circumstances, the decision has been made to significantly reduce further investment in talem's covid program, while still recognizing the ongoing significance of covid-19 globally. ipa will continue to provide updates on talem's progress with chempartner and appreciates the support and patience of its investors during these discussions. conference call: date: thursday, march 16, 2023 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/683815668 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the ability to design and to deliver antibodies to address intracellular targets in a safe and effective manner as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

the program will leverage biostrand’s lensai® full suite of integrated intelligence technology® with libera bio’s multifunctional polymeric nanocapsules (mpn technology®) the alliance has stipulated a minimum of upfront and downstream milestone payments of usd 155 million plus commercial royalties, per product developed victoria, canada and santiago de compostela, spain, march 15, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, today announced that talem therapeutics llc, an independently operating subsidiary of ipa, and libera bio s.l., have signed a collaboration agreement to jointly address intracellular targets. it is estimated that 75% of disease-causing targets are located inside cells1. some of the most elusive cancer targets are expressed inside tumor cells. because they are so difficult to address, they have sometimes been deemed “undruggable” and thus represent high unmet medical needs. numerous pathways intersect inside tumor cells, such as the mapk pathway or the “hedgehog pathway”, and may generate conditions for tumors to develop, grow and evade the immune system. disrupting signals at one or more points within these pathways may slow down the growth of the tumors and inhibit their proliferation. small molecules have been successfully developed to this end, but they often present a significant lack of specificity resulting in toxicity, leading to undesirable side effects for patients. engineering antibodies to force them inside tumor cells has also been attempted, but it is a complex process, often wrought with failure. the collaboration between talem and libera bio will leverage a nanotechnology that has been proven in vivo to deliver antibodies inside tumor cells and provides a potential solution to this medical challenge. libera bio’s multifunctional polymeric nanocapsules (mpn technology®) offer an elegant way to deliver antibodies inside tumor cells. the relevant antibodies are encapsulated in multi-layer nanocapsules of approximately 1/10,000th of a millimeter in diameter. the nanocapsules are specifically designed around the physicochemical properties of antibodies, to protect them from degradation in the blood stream. libera bio believes that this might be the only nanotechnology with in vivo proof of concept of delivering whole antibodies intracellularly. in addition, mpns can deliver other biologic modalities or combinations of a biologic and a small molecule in the same nanocapsule. passively or actively targeted, the mpns deliver these compounds through a cell membrane and to intracellular targets. whole antibodies, close to their natural form, can be delivered in this manner. talem will leverage its antibody discovery and development expertise and access, including without limitation, the lensai technology® from biostrand b.v., an independently operating subsidiary of ipa. biostrand has developed a proprietary, ai-driven platform to optimize the design of such antibodies. biostrand computationally generates and rapidly screens a large set of diverse antibody candidates against a prioritized list of targets, including intracellular targets. talem and libera bio will jointly develop novel antibodies for use with mpn delivery, with the goal of offering them to larger pharma companies to conduct late-stage development and commercialization. the work launches with the investigation of two intracellular targets with very high unmet patient needs to offer options to the oncologists treating them. “as we continue to push the boundaries of cancer therapy, the ability to target intracellular proteins has been the 'holy grail' in oncology. libera bio's ground-breaking approach of enabling biologics to penetrate the cell membrane and reach previously 'undruggable' targets is an exciting development that has the potential to transform the way we treat cancer,” said dr. jennifer bath, ceo and president of immunoprecise antibodies ltd. “the libera bio team has been very impressed with the combination of modern in silico tools and wet lab capabilities at the ipa family of companies. we are looking forward to this alliance that just may yield dozens of new options for cancer treatment,” added olivier jarry, co-founder and ceo of libera bio. 1. verdine gl, walensky ld. the challenge of drugging undruggable targets in cancer: lessons learned from targeting bcl-2 family members. clin cancer res. 2007;13(24):7264-70. doi:10.1158/1078-0432.ccr-07-2184. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com about libera bio. s.l. libera bio s.l. (www.liberabio.com) is a private spanish company, spun off from the university of santiago de compostela (galicia, spain). libera bio aims at changing cancer therapy by allowing biologics to cross the cell membrane and reach “undruggable” intracellular targets: the “holy grail” in oncology. it has conducted preclinical studies of antibodies addressing frequent mutations of kras, a protein involved in a large number of cancers, particularly pancreatic, colorectal and lung cancers. it is now preparing for the enabling studies aiming at a clinical trial authorization. visit http://liberabio.com contact: olivier jarry, ceo, contact@liberabio.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the ability to design and to deliver antibodies to address intracellular targets in a safe and effective manner as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies